Healing & Repair
BPC-157
Body Protection Compound-157
The 15-amino-acid healing peptide derived from gastric juice protein
- FDA Status
- Not FDA-approved · Category 2 (compounding restricted, Sept 2023)
- Class
- Pentadecapeptide · synthetic fragment
- Sequence
- GEPPPGKPADDAGLV
- Half-life
- ~30 min (subcutaneous)
Mechanism of action
- Promotes angiogenesis via VEGF receptor upregulation
- Modulates nitric oxide synthesis (NO/NOS pathway)
- Stabilizes growth-hormone receptor expression in injured tissue
- Cytoprotective effect on gastrointestinal mucosa
Research areas
- Tendon and ligament injury repair (Phase II ongoing)
- Inflammatory bowel disease (ulcerative colitis, Crohn)
- Wound healing and dermal repair
- Gastric ulcer protection (most documented use)
Evidence and clinical data
Strong animal data across 200+ studies. Limited human clinical trials. No published Phase III. The peptide has shown remarkable consistency in rodent models for tissue repair, but bench-to-bedside translation remains the open question.
Safety profile
Excellent animal safety profile across multiple species at doses far exceeding therapeutic ranges. Human safety data is anecdotal. Reported adverse events are rare and mild (injection-site reactions, occasional dizziness).
Why this peptide is trending in 2026: Despite the FDA Category 2 restriction in the US, BPC-157 remains one of the most-discussed peptides in the longevity and recovery community due to its broad regenerative profile.
Educational use only. PeptideAdvance does not sell BPC-157, recommend its use, or provide medical advice. The information above is a summary of published research and regulatory status as of April 2026. Some peptides discussed here are not FDA-approved or are restricted under FDA Category 2 — their use outside of authorized clinical research may carry legal and safety implications. Always consult a licensed healthcare professional.